MNK Key Statistics, Chart & Performance
The current stock price of MNK is 0.3402 USD. In the past month the price decreased by -68.5%.
MNK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About MNK
Company Profile
Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
Company Info
MALLINCKRODT PLC
College Business & Technology Park, Cruiserath,, Blanchardstown
DUBLIN D15 IE
CEO: Mark C. Trudeau
Employees: 2700
MALLINCKRODT PLC / MNK FAQ
Can you describe the business of MALLINCKRODT PLC?
Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
Can you provide the latest stock price for MALLINCKRODT PLC?
The current stock price of MNK is 0.3402 USD. The price decreased by -14.97% in the last trading session.
What is the dividend status of MALLINCKRODT PLC?
MNK does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNK stock?
MNK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is MALLINCKRODT PLC (MNK) stock traded?
MNK stock is listed on the NYSE Arca exchange.
What sector and industry does MALLINCKRODT PLC belong to?
MALLINCKRODT PLC (MNK) operates in the Health Care sector and the Pharmaceuticals industry.
What is the ownership structure of MALLINCKRODT PLC (MNK)?
You can find the ownership structure of MALLINCKRODT PLC (MNK) on the Ownership tab.
MNK Technical Analysis
MNK Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |